New Drug Offers 'Functional Cure' For Dangerous Liver Virus
The experimental drug let patients stop therapy, and 20% kept the virus suppressed for at least six months, researchers reported.
7 Articles
7 Articles
New Drug Offers 'Functional Cure' For Dangerous Liver Virus
WASHINGTON (AP) – A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what's called a "functional cure," researchers reported Thursday.
Experimental Hepatitis B Drug May Offer ‘Functional Cure’ for Some Patients
WASHINGTON (AP) — A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what’s called a “functional cure,” researchers reported Thursday. In two international studies, about 1 in 5 patients given the experimental drug saw their virus reduced to levels low enough for the immune […]
GSK has reported results from two international phase III trials showing that its experimental drug bepirovirsen achieved functional cure rates for chronic hepatitis B of up to 26% in certain patient groups, compared to 0% with normal treatment.
GSK’s hepatitis B drug touts functional curative potential in double Phase III win
Analysts are heralding bepirovirsen as a potentially strong future growth driver for GSK and its infectious disease portfolio.The post GSK’s hepatitis B drug touts functional curative potential in double Phase III win appeared first on Clinical Trials Arena.
A new experimental treatment reduces surface antigen and achieves functional healing in about 19% of participants in two phase III trials, which raises the possibility of abandoning lifetime antiviral therapy for some patients. Read more Bepirovirsen shows functional healing in phase III trials against hepatitis B in News.es.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
